Search - tctmd.com

Displaying 881 - 900 of 2954

Sort: Relevancy | Date

Presentation TCT 2018

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Presenter: Davide Capodanno, Giulio Stefanini, Freek W.A. Verheugt

September 23, 2018

Presentation TCT 2018

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Presenter: Peter Juni, Robert W. Yeh, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Has PIONEER and REDUAL Changed My Practice? What Are the Outstanding Issues?

Presenter: Davide Capodanno, Giulio Stefanini, C. Michael Gibson

September 23, 2018

Presentation TCT 2018

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

Presenter: Peter Juni, Robert W. Yeh, David J. Cohen

September 23, 2018

Presentation TCT 2018

Pharmacotherapy Challenges and Possible Solutions in the PCI Patient on Chronic Oral Anticoagulation

Presenter: Davide Capodanno, Giulio Stefanini, Tullio Palmerini

September 23, 2018

Presentation TCT 2018

SORT OUT IX: Summary and Clinical Implications

Presenter: Andreas Baumbach, Stephan Windecker, Lisette Okkels Jensen

September 23, 2018

Presentation TCT 2018

Most Frequent Errors I See in the Analysis and Interpretation of Trials

Presenter: Peter Juni, Robert W. Yeh

September 23, 2018

Presentation TCT 2018

How to Make Trials Larger, Simpler and Less Expensive

Presenter: Peter Juni, Robert W. Yeh, Matthew T. Roe

September 23, 2018

Presentation TCT 2018

LEADERS FREE II: Summary and Clinical Implications

Presenter: Andreas Baumbach, Stephan Windecker, Mitchell W. Krucoff

September 23, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Presentation TCT 2018

Transcatheter Mitral Valve Replacement: Trial Design Considerations

Presenter: Michael J. Mack, Changfu Wu, John C Laschinger

September 23, 2018

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, William F. Fearon

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Bernard J. Gersh

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

Presenter: Ajay J. Kirtane, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Rasha Al-Lamee

September 23, 2018

Presentation TCT 2018

Aortic Arch Aneurysm: Management and Treatment Options With Case Examples

Presenter: Robert A. Lookstein, Virendra I Patel, Nimesh Desai

September 23, 2018

Presentation TCT 2018

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Presenter: E. Magnus Ohman, Stuart J. Pocock

September 23, 2018

Advertisement

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Has PIONEER and REDUAL Changed My Practice? What Are the Outstanding Issues?

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

Pharmacotherapy Challenges and Possible Solutions in the PCI Patient on Chronic Oral Anticoagulation

SORT OUT IX: Summary and Clinical Implications

Most Frequent Errors I See in the Analysis and Interpretation of Trials

How to Make Trials Larger, Simpler and Less Expensive

LEADERS FREE II: Summary and Clinical Implications

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Transcatheter Mitral Valve Replacement: Trial Design Considerations

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Aortic Arch Aneurysm: Management and Treatment Options With Case Examples

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content